Print 02 May 2015
Setting the new standard in decentralised molecular diagnostics
Bath, UK, 1 May 2015. Atlas Genetics Ltd (“Atlas” or the “Company”), developer of innovative, ultra-rapid diagnostics to enable a ‘test and treat’ solution to infectious diseases, today announces its Annual Summary for 2014.
John Clarkson, CEO of Atlas Genetics, said: “2014 has been a year of very significant achievement for Atlas Genetics. Our io® system is now close to being finalised and approved for sale later this year. The io® Reader is in production and we have received the first 65 instruments from our manufacturing partner LRE (part of the Esterline Group). In June, we announced that we had completed development of the Cartridge and had established a pilot manufacturing capability at Bespak ready for full commercial scale up following launch. With funding secure and our first distribution agreement signed, we believe that Atlas Genetics is now well placed to capture a new POC market to address the increasingly unmet need in the treatment and control of infectious diseases.
“As a credit to all our staff, Atlas Genetics was awarded the prestigious Best for Innovation award from the British Private Equity and Venture Capital Association (BVCA) Management Awards and I would like to thank them for their continuous commitment and hard work.”
For the full Annual Summary, please go to: www.atlasgenetics.com
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
20 September 2017
19 September 2017